Search details
1.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 390(14): 1265-1276, 2024 Apr 11.
Article
in English
| MEDLINE | ID: mdl-38598794
2.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
N Engl J Med
; 389(2): 137-147, 2023 Jul 13.
Article
in English
| MEDLINE | ID: mdl-37272535
3.
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
J Transl Med
; 22(1): 326, 2024 Apr 02.
Article
in English
| MEDLINE | ID: mdl-38566102
4.
A novel image deep learning-based sub-centimeter pulmonary nodule management algorithm to expedite resection of the malignant and avoid over-diagnosis of the benign.
Eur Radiol
; 34(3): 2048-2061, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37658883
5.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol
; 20(15): 969-980, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38095056
6.
IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer.
Chin J Cancer Res
; 36(2): 103-113, 2024 Apr 30.
Article
in English
| MEDLINE | ID: mdl-38751442
7.
Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
Cancer
; 129(20): 3239-3251, 2023 10 15.
Article
in English
| MEDLINE | ID: mdl-37282666
8.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(18): 1711-1723, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32955177
9.
Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial.
Cancer Immunol Immunother
; 72(5): 1261-1272, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36427086
10.
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004).
Cancer Immunol Immunother
; 72(7): 2257-2265, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36871274
11.
PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma.
Cancer Immunol Immunother
; 72(4): 881-893, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-36121452
12.
Heterogeneity in the immune microenvironment of bone metastasis in driver-positive non-small cell lung cancer.
Mol Carcinog
; 62(7): 1001-1008, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37067398
13.
Expression Changes in Programmed Death Ligand 1 from Precancerous Lesions to Invasive Adenocarcinoma in Subcentimeter Pulmonary Nodules: A Large Study of 2022 Cases in China.
Ann Surg Oncol
; 30(12): 7400-7411, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37658270
14.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37306090
15.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol
; 19(1): 61-75, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36656302
16.
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 23(2): 209-219, 2022 02.
Article
in English
| MEDLINE | ID: mdl-35038429
17.
Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study.
Cancer Immunol Immunother
; 71(6): 1393-1402, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-34668977
18.
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.
BMC Med
; 20(1): 197, 2022 05 30.
Article
in English
| MEDLINE | ID: mdl-35644609
19.
Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases.
J Transl Med
; 20(1): 74, 2022 02 05.
Article
in English
| MEDLINE | ID: mdl-35123506
20.
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials.
Expert Opin Emerg Drugs
; 27(2): 111-126, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35385682